Cancer vaccines have so far generated more headlines than health benefits. Even some of the success stories, like Dendreon, have faltered once faced with trying to commercialize an oncology immunotherapy. Yet the vast potential means people continue to talk up the sector.
Social issues have held back uptake of GlaxoSmithKline and Merck human papillomavirus (HPV) vaccines in the U.S., but globally the problem is more fundamental--the shots cost too much. It is these low-income countries--where 85% of cervical cancer cases occur--that need the vaccines most though.
In a study trialed by the University of Pennsylvania, researchers have developed a vaccine using trial participants' own blood and tumor cells.
The road toward developing a non-Hodgkin's lymphoma vaccine is littered with failures. Two companies, Genitope and Favrille, had trials fail in 2007 and 2008 and then quickly closed down shop. The challenges were writ large again last week when Biovest filed for bankruptcy--for the second time in 5 years.
The history of cancer vaccines is littered with candidates that showed great promise in the lab, only to flunk clinical trials. Now, scientists think they know why--the vaccines are self-sabotaging.
On Feb. 15, Australian boys began receiving Gardasil as part of a $21 million program geared toward vaccinating 12- and 13-year-olds.
Vaccine-makers Merck and GlaxoSmithKline could boost revenue brought in by their HPV vaccines--Gardasil and Cervarix--if more boys received the shot regimen. A Boston University School of Medicine study shows more parents and guardians saw benefits than drawbacks to vaccinating boys.
Cancers caused by human papillomavirus rose in the past decade, a fact that may irk HPV vaccine makers Merck and GlaxoSmithKline.
PsiOxus Therapeutics nabbed £1.7 million ($2.7 million) from the U.K. government-backed Biomedical Catalyst to start a Phase I/II clinical trial of its cancer vaccine.
This FierceVaccines special report spotlights 10 promising therapeutic vaccines on their way through clinical development that might just change the face of cancer treatment. Many of them are in the early steps of R&D, so it may be a while, especially for those that are first-in-class, or that are bringing a new technology to the table, but they could be the first baby steps to a brave new world. Click here to check out the full report >>